The cardiac effects of hydroxychloroquine in immune-mediated rheumatologic diseases.
Journal
JAAPA : official journal of the American Academy of Physician Assistants
ISSN: 1547-1896
Titre abrégé: JAAPA
Pays: United States
ID NLM: 9513102
Informations de publication
Date de publication:
01 Apr 2022
01 Apr 2022
Historique:
entrez:
29
3
2022
pubmed:
30
3
2022
medline:
1
4
2022
Statut:
ppublish
Résumé
Hydroxychloroquine, when used to treat patients with rheumatoid arthritis or systemic lupus erythematosus, has been found to reduce cardiovascular disease (CVD). The drug also has been associated with cardiac adverse reactions such as conduction abnormalities. This article reviews the reduction of CVD and the cardiac adverse reactions associated with hydroxychloroquine.
Identifiants
pubmed: 35348541
doi: 10.1097/01.JAA.0000805852.13262.54
pii: 01720610-202204000-00008
doi:
Substances chimiques
Hydroxychloroquine
4QWG6N8QKH
Types de publication
Journal Article
Review
Langues
eng
Pagination
51-53Informations de copyright
Copyright © 2022 American Academy of Physician Associates.
Références
Naksuk N, Lazar S, Peeraphatdit TB. Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol. Eur Heart J Acute Cardiovasc Care . 2020;9(3):215–221.
Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis . 2010;69(1):20–28.
Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol . 2016;68(1):1–26.
Doyno C, Sobieraj DM, Baker WL. Toxicity of chloroquine and hydroxychloroquine following therapeutic use or overdose. Clin Toxicol (Phila) . 2021;59(1):12–23.
Hydroxychloroquine sulfate tablets prescribing information. https://products.sanofi.us/hydroxychloroquine/hydroxychloroquine.html . Accessed November 5, 2021.
Tonnesmann E, Kandolf R, Lewalter T. Chloroquine cardiomyopathy—a review of the literature. Immunopharmacol Immunotoxicol . 2013;35(3):434–442.
dos Reis Neto ET, Kakehasi AM, de Medeiros Pinheiro M, et al. Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases. Adv Rheumatol . 2020;60(1):32.
Giannelou M, Mavragani CP. Cardiovascular disease in systemic lupus erythematosus: a comprehensive update. J Autoimmun . 2017;82:1–12.
Barbhaiya M, Feldman CH, Guan H, et al. Race/ethnicity and cardiovascular events among patients with systemic lupus erythematosus. Arthritis Rheumatol . 2017;69(9):1823–1831.
Aviña-Zubieta JA, Choi HK, Sadatsafavi M, et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum . 2008;59(12):1690–1697.
Daniel CM, Davila L, Makris UE, et al. Ethnic disparities in atherosclerotic cardiovascular disease incidence and prevalence among rheumatoid arthritis patients in the United States: a systematic review. ACR Open Rheumatol . 2020;2(9):525–532.
Fransen J, Kazemi-Bajestani SMR, Bredie SJH, Popa CD. Rheumatoid arthritis disadvantages younger patients for cardiovascular diseases: a meta-analysis. PLoS One . 2016;11(6):e0157360.
Liu D, Li X, Zhang Y, et al. Chloroquine and hydroxychloroquine are associated with reduced cardiovascular risk: a systematic review and meta-analysis. Drug Des Dev Ther . 2018;12:1685–1695.
Rempenault C, Combe B, Barnetche T, et al. Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis . 2018;77(1):98–103.
Chatre C, Roubille F, Vernhet H, et al. Cardiac complications attributed to chloroquine and hydroxychloroquine: a systematic review of the literature. Drug Saf . 2018;41(10):919–931.
Myasoedova E, Kurmann R, Crowson CS, et al. Increased risk of heart failure with prolonged use of hydroxychloroquine in patients with rheumatoid arthritis [abstract]. Arthritis Rheumatol . 2018;70(suppl 10). https://acrabstracts.org/abstract/increased-risk-of-heart-failure-with-prolonged-use-of-hydroxychloroquine-in-patients-with-rheumatoid-arthritis . Accessed November 5, 2021.